Skip to content
Search

Latest Stories

Pharmacist wins £58,000 compensation in racial harassment case against Boots

Pharmacist wins £58,000 compensation in racial harassment case against Boots

An Employment Tribunal upheld 7 claims of harassment related to race brought by the pharmacist against Boots and one of its pharmacy technicians

A tribunal has ordered Boots to pay over £58,000 in compensation and costs to a pharmacist who was racially profiled at work.

S.Famojuro, a black pharmacist of Nigerian national origin, experienced racial harassment from pharmacy team members during a shift on 18 July 2020.


The Pharmacists’ Defence Association (PDA), the independent trade union for pharmacists, represented the pharmacist throughout the internal grievance processes and at the Employment Tribunal hearing.

In a detailed written judgment, the pharmacy team members and company managers were heavily criticised by the Tribunal, after finding that a pre-registration pharmacy technician and a pharmacy advisor had undermined Famojuro in his professional role as the Responsible Pharmacist (RP) and insulted him.

The pharmacist lodged a grievance with Boots regarding his treatment, but it took the company over four months to initiate the investigation and set a meeting date, and this was only done after the PDA intervened to address the unacceptable delays.

However, the Judge described the grievance investigation conducted by an experienced store manager as “simply not fit for purpose” and lacking a “basic level of competence.”

The grievance manager was found to be inadequately trained for conducting grievances into serious allegations of discrimination, and there were unacceptable delays in dealing with the complaints.

The Tribunal concluded that Boots' actions had seriously damaged the relationship of mutual trust and confidence, leading to Famojuro's resignation, which was determined to be a case of constructive unfair dismissal.

The grievance outcome was issued on 15 January 2021, with all of the pharmacist's complaints being dismissed, except for one regarding delays in the investigation.

Unsatisfied, the pharmacist appealed against the outcome, leading to the appointment of an area manager to hear the appeal.

However, the appeal manager did nothing to probe further the conduct of the pharmacy technician and pharmacy advisor, with the Tribunal noting that his inquiry was "superficial and lacked insight."

After receiving the appeal outcome, the pharmacist resigned with a notice on 3 April 2021. The apology arrived on 12 May 2021, almost 6 weeks after his resignation.

The Tribunal described this as “the classic formulation of a non-apology” noting that it “must have rubbed salt in the Claimant’s wounds”.

Following a 5-day hearing earlier this year, the Tribunal upheld 7 claims of harassment related to race brought by the pharmacist against Boots and the pharmacy technician, as well as his claim of constructive unfair dismissal.

In a remedy hearing, the Tribunal awarded Famojuro £45,263.11 for loss of earnings, injury to feelings, aggravated damages, an uplift for failure to follow the ACAS Code, and interest. Additionally, costs of £13,357.25 were awarded to the PDA, bringing the total compensation and costs to £58,620.36.

Mark Pitt, General Secretary of the PDA Union said: “Rather than properly investigate Mr Famojuro’s complaints and condemn the racist behaviour of their employees at the time of the incident, the company supported them throughout, denying any racism had occurred.

“Consequently, Mr Famojuro was put through 4 years of stress and court proceedings to secure justice for his discriminatory treatment.

“The PDA legal team have been behind him all the way and the high award and aggravated damages reflect the extreme displeasure of the employment tribunal panel at the conduct of company and its witnesses, some of whom were found to have lied and fabricated evidence. “

Wai Chan, Vice President of the PDA BAME Pharmacists Network which leads anti-racist activity for the PDA, stated that they will review this case to inform their future activity.”

The PDA emphasised that unlawful discrimination related to race is unacceptable, and urges members who encounter discrimination at work to seek advice from the PDA Member Support Centre.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less